Gilead Sciences, Inc. (BMV:GILD)

Market Cap	2.75T
Revenue (ttm)	544.30B
Net Income (ttm)	119.01B
Shares Out	n/a
EPS (ttm)	94.50
PE Ratio	23.07
Forward PE	14.02
Dividend	61.48 (2.89%)
Ex-Dividend Date	Jun 13, 2025

Volume	6
Average Volume	713
Open	2,223.70
Previous Close	2,130.00
Day's Range	2,223.70 - 2,223.70
52-Week Range	1,390.00 - 2,347.00
Beta	0.35
RSI	81.17
Earnings Date	Aug 1, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD